rFXIII Congenital deficiency
:Haemostatic agent
:Phase 3
Novo Nordisk is developing a recombinant FXIII intended to treat congenital FXIII deficiency (NN1841).
FXIII is part of the coagulation cascade and functions by cross-linking fibrin to increase the stability of the clot, making it mechanically stronger and more rigid and elastic.
- Company announcements
- Novo Nordisk provides update on corporate strategy at its Capital Markets Day (26 Sep 2008)
- Novo Nordisk's Capital Markets Day 2004 (05 Oct 2004)
- Read more company announcements
- Press releases
- Novo Nordisk begins phase 1 study with rFXIII in cardiac surgery (18 Oct 2005)
- Read more press releases
- Scientific abstracts
No scientific abstracts matching the search criteria
